Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8778)
All Articles published online
|
Publishing Process of This Article
|
Aug 27, 2020 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sofogianni A, Filippidis A, Chrysavgis L, Tziomalos K, Cholongitas E. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. World J Hepatol 2020; 12(8): 493-505 [PMID: 32952876 DOI: 10.4254/wjh.v12.i8.493] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i8/493.htm |
| Number | Citing Articles |
| 1 |
Demelza Emmerton, Ahmed Abdelhafiz. Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people. Hospital Practice 2021; 49(3): 164 doi: 10.1080/21548331.2021.1905414
|
| 2 |
Khaoula Errafii, Olfa Khalifa, Neyla S. Al-Akl, Abdelilah Arredouani. Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism. Biomedicines 2022; 10(5): 1020 doi: 10.3390/biomedicines10051020
|
| 3 |
Poonam Yadav, Amit Khurana, Jasvinder Singh Bhatti, Ralf Weiskirchen, Umashanker Navik. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective. Pharmacological Research 2022; 184: 106426 doi: 10.1016/j.phrs.2022.106426
|
| 4 |
Rajaa Nahra, Tao Wang, Kishore M. Gadde, Jan Oscarsson, Michael Stumvoll, Lutz Jermutus, Boaz Hirshberg, Philip Ambery. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care 2021; 44(6): 1433 doi: 10.2337/dc20-2151
|
| 5 |
Lampros G. Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongitas. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. International Journal of Molecular Sciences 2024; 25(7): 3832 doi: 10.3390/ijms25073832
|
| 6 |
Maria Corina Plaz Torres, Ariel Jaffe, Rachel Perry, Elisa Marabotto, Mario Strazzabosco, Edoardo G. Giannini. Diabetes medications and risk of HCC. Hepatology 2022; 76(6): 1880 doi: 10.1002/hep.32439
|
| 7 |
Alan J. Sinclair, Daniel Pennells, Ahmed H. Abdelhafiz. Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotype. Aging Clinical and Experimental Research 2022; 34(9): 1949 doi: 10.1007/s40520-022-02142-8
|
| 8 |
Ja Young Jeon, Hae Jin Kim. Stroke Revisited: Diabetes in Stroke. Stroke Revisited 2021; : 167 doi: 10.1007/978-981-16-5123-6_14
|
| 9 |
Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, Terry D. Hinds, David E. Stec. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clinical Science 2022; 136(18): 1347 doi: 10.1042/CS20220572
|
| 10 |
Ameng Shi, Ting Li, Ying Zheng, Yahua Song, Haitao Wang, Na Wang, Lei Dong, Haitao Shi. Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.693048
|
| 11 |
Veronika A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines 2022; 10(2): 274 doi: 10.3390/biomedicines10020274
|
| 12 |
Alan J. Sinclair, Ahmed H. Abdelhafiz. Metabolic Impact of Frailty Changes Diabetes Trajectory. Metabolites 2023; 13(2): 295 doi: 10.3390/metabo13020295
|
| 13 |
Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy 2024; 9(1) doi: 10.1038/s41392-024-01931-z
|
| 14 |
Daniela Maria Tanase, Evelina Maria Gosav, Daniela Petrov, Alina Ecaterina Jucan, Cristina Mihaela Lacatusu, Mariana Floria, Claudia Cristina Tarniceriu, Claudia Florida Costea, Manuela Ciocoiu, Ciprian Rezus. Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets. Diagnostics 2021; 11(11): 2053 doi: 10.3390/diagnostics11112053
|
| 15 |
Hae Jin Kim. Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist. The Journal of Korean Diabetes 2021; 22(2): 126 doi: 10.4093/jkd.2021.22.2.126
|
| 16 |
Maja Cigrovski Berkovic, Tanja Rezic, Ines Bilic-Curcic, Anna Mrzljak. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. World Journal of Clinical Cases 2022; 10(20): 6759-6768 doi: 10.12998/wjcc.v10.i20.6759
|
| 17 |
Omar Hegazi, Samer Alalalmeh, Moyad Shahwan, Ammar Jairoun, Mansour Alourfi, Ghfran Bokhari, Abdullah Alkhattabi, Saeed Alsharif, Mohannad Aljehani, Abdulmalik Alsabban, Mohammad Almtrafi, Ysear Zakri, Abdullah AlMahmoud, Khalid Alghamdi, Ahmed Ashour, Nasser Alorfi. Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis. Diabetes, Metabolic Syndrome and Obesity 2024; : 545 doi: 10.2147/DMSO.S448476
|
| 18 |
Khamis Al Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Angelo Maria Patti, Khalid Al Waili, Khalid Al Rasadi, Marcello Ciaccio, Manfredi Rizzo. Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies. Frontiers in Nutrition 2024; 11 doi: 10.3389/fnut.2024.1355732
|
| 19 |
Manisha Yadav, Smriti Verma, Purnima Tiwari, Madhav Nilakanth Mugale. Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives. Life Sciences 2024; 353: 122934 doi: 10.1016/j.lfs.2024.122934
|
| 20 |
J. Bojunga, A. Beckerbauer. Diabetes und Gastroenterologie – Update 2021. Der Diabetologe 2021; 17(5): 528 doi: 10.1007/s11428-021-00780-6
|
| 21 |
Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye, Bihui Zhong. Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials. Obesity Reviews 2024; 25(6) doi: 10.1111/obr.13727
|
| 22 |
Joanna Michałowska, Ewa Miller-Kasprzak, Paweł Bogdański. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. Nutrients 2021; 13(2): 351 doi: 10.3390/nu13020351
|
| 23 |
Ana Petrovic, Dunja Igrec, Karla Rozac, Kristina Bojanic, Lucija Kuna, Tea Omanovic Kolaric, Vjera Mihaljevic, Renata Sikora, Robert Smolic, Marija Glasnovic, George Y. Wu, Martina Smolic. The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD. Current Issues in Molecular Biology 2023; 45(6): 4544 doi: 10.3390/cimb45060288
|
| 24 |
Mai Salah Nour, Zeinab Abd El-Hay Sakara, Nawal Awad Hasanin, Shereen Mohamed Hamed. Histological and immunohistochemical study of the effect of liraglutide in experimental model of non-alcoholic fatty liver disease. Egyptian Journal of Basic and Applied Sciences 2023; 10(1): 342 doi: 10.1080/2314808X.2023.2204258
|